Peace in the valley of RNAi
A pair of one-time courtroom opponents have found a way to coexist, as Alnylam Pharmaceuticals and Dicerna Pharmaceuticals struck a deal to share the spoils of some rare disease treatments.
As STAT’s Kate Sheridan reports, the two companies are harmonizing their pipelines when it comes to alpha-1 antitrypsin deficiency and primary hyperoxaluria type 1, two rare genetic disorders. Under the agreement, Dicerna will cover the costs of developing either its own or Alnylam’s version of the alpha-1 antitrypsin deficiency drug candidate, while Alnylam will have the option to commercialize it outside the U.S.
The two companies both use the Nobel Prize-winning technique known as RNA interference to treat disease, and the overlap of their technologies has put them at odds in the past. Two years ago, the two settled a patent lawsuit related to RNAi.
Read more.
As STAT’s Kate Sheridan reports, the two companies are harmonizing their pipelines when it comes to alpha-1 antitrypsin deficiency and primary hyperoxaluria type 1, two rare genetic disorders. Under the agreement, Dicerna will cover the costs of developing either its own or Alnylam’s version of the alpha-1 antitrypsin deficiency drug candidate, while Alnylam will have the option to commercialize it outside the U.S.
The two companies both use the Nobel Prize-winning technique known as RNA interference to treat disease, and the overlap of their technologies has put them at odds in the past. Two years ago, the two settled a patent lawsuit related to RNAi.
Read more.
.png)
No hay comentarios:
Publicar un comentario